Primaquine phosphate: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Primaquine phosphate}} {{CMG}}; {{AE}} {{chetan}} ==Overview== ==Category== ==US Brand Names== ==FDA Package Insert== ''' Primaquine phosphate description|..." |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Primaquine''' (or '''primaquine phosphate''') is a medication used in the treatment of [[malaria]] and [[Pneumocystis pneumonia]]. It is a member of the [[8-aminoquinoline]] group of drugs that includes [[tafenoquine]] and [[pamaquine]]. Primaquine was first synthesised by [[Robert Elderfield]] of [[Columbia University]] in the 1940's.<ref>{{cite journal|author = Edgcomb JH, Arnold J, Young EH, ''et al.'' | year = 1950 | title = Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report. | journal = Journal National Malaria Society | volume = 9 | issue = 4 | pages = 285–92 | pmid = 14804087}}</ref> | |||
==Category== | ==Category== | ||
Revision as of 04:47, 8 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Primaquine (or primaquine phosphate) is a medication used in the treatment of malaria and Pneumocystis pneumonia. It is a member of the 8-aminoquinoline group of drugs that includes tafenoquine and pamaquine. Primaquine was first synthesised by Robert Elderfield of Columbia University in the 1940's.[1]
Category
US Brand Names
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages